Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.10.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Dan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Lung Transplantation, Azithromycin, Atorvastatin. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Beijing Medical and Health Foundation.
Abstract (Originalsprache)
OBJECTIVE: To assess the impact of long-term atorvastatin (ATO) therapy on reducing recipient inflammation and immune response, thus lowering the risk of chronic lung allograft dysfunction (CLAD) in lung transplant recipients. This study aimed to investigate the effects of ATO on overall survival, lung function recovery, and its influence on inflammatory factors alongside azithromycin (AZI) prophylaxis. METHODS: This retrospective single-center study included lung transplant recipients from January 2017 to December 2022. Patients who survival >1 year after lung transplantation and who were receiving AZI prophylaxis for >6 months were selected. Outcome measures involved pulmonary function assessments at various time points after AZI treatment, complete blood cell analysis, and inflammatory factor evaluations. RESULTS: The incidence of CLAD was significantly lower in the long-term ATO group compared with those not on ATO (P = .011). Long-term ATO treatment significantly delayed CLAD onset after lung transplantation (850 days vs. 630 days; P = .041), with patients showing notably enhanced lung function recovery within 6 months of AZI therapy compared with the non-ATO group. Neutrophil levels decreased in patients with CLAD, and interleukin-6 concentrations significantly decreased in the AZI + ATO group compared with the AZI group. Overall patient survival was significantly better in the AZI+ATO group than in the AZI group (P = .02). CONCLUSION: In cases where CLAD develops despite AZI prophylaxis, long-term ATO treatment may lead to short-term improvements in lung function. It could also decrease inflammation levels in lung transplant recipients and enhance overall survival. The combination of AZI and long-term ATO therapy may be beneficial for CLAD prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
- Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Electronic address: lipengmei@yeah.net.
Förderung
- Beijing Medical and Health Foundation
Zitieren
APA
Zhang, D., Wang, X., Du, W., & Li, P. (2024). Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.10.015
Vancouver
Zhang D, Wang X, Du W, Li P. Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.10.015
BibTeX
@article{Zhang2024,
author = {Zhang, Dan and Wang, Xiaoxing and Du, Wenwen and Li, Pengmei},
title = {Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.10.015}
}
EUVIMED